Novartis gets a PSMAfore green flag at last
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
The company is stepping back in second-line breast cancer.
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
One step forward, two steps back for biotech.
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
Another SERD catalyst and the son of Darzalex take centre stage.
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.